## https://www.asahi.com/articles/ASR935F6GR91PLBJ001.html?iref=comtop_Tech_science_04; last accessed: 20230904

> 世界にたった1人の病気でも　治験参加へ道筋、薬開発の可能性探る

Even if there is only one patient in the world, this company is looking into developing the medicine, so that the patient can participate in the clinical trials

> 瀬川茂子

SEGAWA, Shigeko

> 2023年9月3日 18時30分

2023-09-03T18:30

### KEYPHRASE

>　世界に1人しかいない病気の患者にも薬を届けたい――。患者数が少なすぎて、新薬の開発に必要な治験ができない病気や、進行が早くて治験が待てない難病患者の創薬研究をめざすプロジェクトを日本医療研究開発機構（AMED）が始めた。

They want to deliver medicine to patients, even if there exists only one such illness in the world. Because the patient count is too small, this Japanese medical treatment R&D company (AMED) started a project, which aims to develop medicine for patients with difficult illnesses, and who cannot wait for the clinical trials, because their illnesses have advanced too early, such that the necessary clinical trials cannot anymore be done to develop the medicine. 

### REFERENCE

GOOGLE SEARCH ENGINE: TRANSLATE
